- Home
- INMB vs RPTX Comparison
INMB vs RPTX Comparison
Compare INMB & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- RPTX
- Stock Information
- Founded
- INMB 2015
- RPTX 2016
- Country
- INMB United States
- RPTX Canada
- Employees
- INMB N/A
- RPTX N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- RPTX Health Care
- Exchange
- INMB Nasdaq
- RPTX Nasdaq
- Market Cap
- INMB 68.9M
- RPTX 69.2M
- IPO Year
- INMB 2019
- RPTX 2020
- Fundamental
- Price
- INMB $1.89
- RPTX $1.70
- Analyst Decision
- INMB Buy
- RPTX Strong Buy
- Analyst Count
- INMB 4
- RPTX 3
- Target Price
- INMB $9.53
- RPTX $4.50
- AVG Volume (30 Days)
- INMB 806.4K
- RPTX 91.2K
- Earning Date
- INMB 10-30-2025
- RPTX 11-06-2025
- Dividend Yield
- INMB N/A
- RPTX N/A
- EPS Growth
- INMB N/A
- RPTX N/A
- EPS
- INMB N/A
- RPTX N/A
- Revenue
- INMB $50,000.00
- RPTX $250,000.00
- Revenue This Year
- INMB $142.83
- RPTX N/A
- Revenue Next Year
- INMB $14,780.90
- RPTX N/A
- P/E Ratio
- INMB N/A
- RPTX N/A
- Revenue Growth
- INMB N/A
- RPTX N/A
- 52 Week Low
- INMB $1.86
- RPTX $0.89
- 52 Week High
- INMB $11.64
- RPTX $4.07
- Technical
- Relative Strength Index (RSI)
- INMB 31.89
- RPTX 68.84
- Support Level
- INMB $1.86
- RPTX $1.66
- Resistance Level
- INMB $2.00
- RPTX $1.60
- Average True Range (ATR)
- INMB 0.13
- RPTX 0.05
- MACD
- INMB 0.01
- RPTX 0.01
- Stochastic Oscillator
- INMB 7.41
- RPTX 90.43
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.